Market Coverage
National testing presence across China.
Biomarker Testing Intelligence Across Real Clinical Settings
Supporting companion diagnostics, testing strategy, testing adoption, reimbursement status, and treatment pathway understanding across precision medicine markets.
National CoverageCompanion DiagnosticsReal-World Data
China Precision Medicine Landscape
Real-world visibility into laboratories, testing, market access, and diagnostics adoption.
Laboratory Mapping
Hospital and third-party testing laboratory visibility.
Testing Activity
Biomarker utilization and testing patterns.
Platform Adoption
Platform and methodology distribution.
Market Access
Provincial reimbursement and access environment.
Real-World Data
Operational diagnostics intelligence from active laboratories.
Jianji™ Intelligence Platform
Real-time view of the Chinese laboratory CDx testing landscape — institution coverage, regulatory, methodology and platform adoption, reimbursement, and market access.
- National Testing Map
- Platform
- Regulatory & Reimbursement
- Analyst Notes
Jianji™ Platform
China · CDx CoverageNational Testing Map
Schematic
Active Institutions
77
Provinces Covered
19
Top Institutions
- Fudan CancerShanghai
- PUMC HospitalBeijing
- Sun Yat-senGuangzhou
- Tianjin CancerTianjin
- West ChinaChengdu
Precision medicine adoption still varies significantly across hospitals, laboratories, and regions.
Laboratory capability, testing access, reimbursement, and assay adoption continue to vary significantly across China.
BYTEclt · China Precision Diagnostics
Diagnostics Strategy
Built Around Testing Adoption
BYTEclt works on biomarker testing, companion diagnostics, and launch readiness across China's precision medicine market.
We work with pharma, diagnostics, and biotech teams on how biomarker testing actually behaves across Chinese hospitals and third-party testing laboratories — testing capability and methodology, regional reimbursement, send-out testing, and hospital-level adoption.
Jianji™ is BYTEclt's internal platform for analyzing companion diagnostic adoption across Chinese hospitals and third-party testing laboratories.
Selected Work
Representative assessments related to biomarker testing, companion diagnostics, and launch planning.
HER2-Low Testing Assessment
Assessment of HER2-low testing adoption across Chinese pathology laboratories and third-party testing providers, including assay methodology, testing availability, and estimated testing volume relevant to companion diagnostic launch planning.
China · Companion Diagnostics · HER2-low
DLBCL COO / CDx Readiness
Evaluation of biomarker testing readiness and companion diagnostic adoption patterns associated with DLBCL COO classification across hospitals and laboratories in China.
DLBCL · Biomarker Testing · Launch Readiness
Observations
- Testing adoption rarely scales uniformly across regions.
- Commercial launch assumptions often fail at the laboratory level.
- Testing methodology variation remains a practical launch constraint.